1. Home
  2. CYTH vs AAME Comparison

CYTH vs AAME Comparison

Compare CYTH & AAME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CYTH
  • AAME
  • Stock Information
  • Founded
  • CYTH 1990
  • AAME 1968
  • Country
  • CYTH United States
  • AAME United States
  • Employees
  • CYTH N/A
  • AAME N/A
  • Industry
  • CYTH Biotechnology: Pharmaceutical Preparations
  • AAME Life Insurance
  • Sector
  • CYTH Health Care
  • AAME Finance
  • Exchange
  • CYTH Nasdaq
  • AAME Nasdaq
  • Market Cap
  • CYTH 22.0M
  • AAME 31.4M
  • IPO Year
  • CYTH N/A
  • AAME N/A
  • Fundamental
  • Price
  • CYTH $0.81
  • AAME $1.70
  • Analyst Decision
  • CYTH Buy
  • AAME
  • Analyst Count
  • CYTH 3
  • AAME 0
  • Target Price
  • CYTH $0.95
  • AAME N/A
  • AVG Volume (30 Days)
  • CYTH 32.7K
  • AAME 6.5K
  • Earning Date
  • CYTH 11-12-2024
  • AAME 11-11-2024
  • Dividend Yield
  • CYTH N/A
  • AAME 2.35%
  • EPS Growth
  • CYTH N/A
  • AAME N/A
  • EPS
  • CYTH N/A
  • AAME N/A
  • Revenue
  • CYTH $1,132,430.00
  • AAME $186,001,000.00
  • Revenue This Year
  • CYTH N/A
  • AAME N/A
  • Revenue Next Year
  • CYTH $24.49
  • AAME N/A
  • P/E Ratio
  • CYTH N/A
  • AAME N/A
  • Revenue Growth
  • CYTH 24.65
  • AAME N/A
  • 52 Week Low
  • CYTH $0.59
  • AAME $1.43
  • 52 Week High
  • CYTH $2.12
  • AAME $3.00
  • Technical
  • Relative Strength Index (RSI)
  • CYTH 57.39
  • AAME 54.83
  • Support Level
  • CYTH $0.75
  • AAME $1.51
  • Resistance Level
  • CYTH $0.80
  • AAME $1.73
  • Average True Range (ATR)
  • CYTH 0.06
  • AAME 0.05
  • MACD
  • CYTH 0.01
  • AAME 0.00
  • Stochastic Oscillator
  • CYTH 100.00
  • AAME 86.32

About CYTH Cyclo Therapeutics Inc.

Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.

About AAME Atlantic American Corporation

Atlantic American Corp operates in specialty markets within the life and health and property and casualty insurance industries. The company has two segments: American Southern, It provides property and casualty insurance including bodily injury and property damage liability coverage, uninsured motorist coverage, and physical damage coverage for commercial accounts. It also provides tailored business automobile insurance coverage, on a multi-year contract basis, to state governments and local municipalities, and Bankers Fidelity, the company's life and health operations offer a variety of life and supplemental health products including ordinary and term life insurance, Medicare supplement, and other health insurance. It earns revenue from the collection of premiums and investment income.

Share on Social Networks: